NextCure (MUN:2US) - Prezzo delle azioni, notizie e analisi

2US Panoramica delle azioni

A clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function.

Informazioni sull'azienda

2US analisi fondamentale
Punteggio fiocco di neve
Valutazione	2/6
Crescita futura	0/6
Prestazioni passate	0/6
Salute finanziaria	6/6
Dividendi	0/6

Premi

Analisi del rischio

Le azioni sono altamente illiquide

Si prevede che gli utili diminuiranno in media di 2.6% all'anno per i prossimi 3 anni

Realizza un fatturato inferiore a 1 milione di dollari ( $0 )

Non ha una capitalizzazione di mercato significativa ( €45M )

+ 1 più rischio

NextCure, Inc. Concorrenti

2invest

XTRA:2INV

€59.8m

4SC

DB:VSC

€61.5m

Medigene

XTRA:MDG1

€25.0m

Heidelberg Pharma

XTRA:HPHA

€111.9m

Storia dei prezzi e prestazioni

Riepilogo dei massimi storici, delle variazioni e dei cali di prezzo di tutti i tempi per NextCure
Prezzi storici delle azioni
Prezzo attuale dell'azione	US$1.37
Massimo di 52 settimane	US$1.47
Minimo di 52 settimane	US$1.11
Beta	0.67
1Variazione di 1 mese	0%
Variazione a 3 mesi	8.57%
Variazione di 1 anno	n/a
3Variazione a 3 anni	-77.99%
Variazione a 5 anni	n/a
Variazione dall'IPO	-92.59%

Notizie e aggiornamenti recenti

Recent updates

Rendimenti per gli azionisti

	2US	DE Biotechs	DE Mercato
7D	0%	0.7%	1.1%
1Y	n/a	-17.7%	12.5%

Ritorno vs Industria: Dati insufficienti per determinare come si è comportato 2US rispetto al settore German Biotechs.

Rendimento vs Mercato: Dati insufficienti per determinare la performance di 2US rispetto al mercato German.

Volatilità dei prezzi

Is 2US's price volatile compared to industry and market?
2US volatility
2US Average Weekly Movement	n/a
Biotechs Industry Average Movement	5.5%
Market Average Movement	4.9%
10% most volatile stocks in DE Market	11.6%
10% least volatile stocks in DE Market	2.4%

Prezzo delle azioni stabile: 2US non ha avuto una volatilità dei prezzi significativa negli ultimi 3 mesi.

Volatilità nel tempo: Dati insufficienti per determinare la variazione della volatilità di 2US nell'ultimo anno.

Informazioni sull'azienda

Fondato	I dipendenti	AMMINISTRATORE DELEGATO	Sito web
2015	82	Michael Richman	www.nextcure.com

NextCure, Inc. Riepilogo dei fondamenti

Come si confrontano gli utili e i ricavi di NextCure con la sua capitalizzazione di mercato?
2US statistiche fondamentali
Capitalizzazione di mercato	€41.33m
Guadagni(TTM)	-€58.86m
Ricavi(TTM)	n/a

0.0x

Rapporto P/S

-0.7x

Rapporto P/E

2US è sopravvalutato?

Vedi Fair Value e analisi di valutazione

Guadagni e ricavi

Statistiche chiave sulla redditività dall'ultima relazione sugli utili (TTM)
2US Conto economico (TTM)
Ricavi	US$0
Costo del fatturato	US$0
Profitto lordo	US$0
Altre spese	US$63.73m
Guadagni	-US$63.73m

Ultimi guadagni dichiarati

Mar 31, 2024

Prossima data di guadagno

n/a

Utile per azione (EPS)	-2.28
Margine lordo	0.00%
Margine di profitto netto	0.00%
Rapporto debito/patrimonio netto	0%

Come si è comportato 2US nel lungo periodo?

Vedi performance storica e confronto

2US Panoramica delle azioni

Premi

Analisi del rischio

NextCure, Inc. Concorrenti

XTRA:2INV

€59.8m

DB:VSC

€61.5m

XTRA:MDG1

€25.0m

XTRA:HPHA

€111.9m

Storia dei prezzi e prestazioni

Notizie e aggiornamenti recenti

NextCure, Inc. Reports Preclinical Data for LNCB74 and Additional Clinical Biomarker Data for NC410 Combo At Society for Immunotherapy of Cancer Annual Meeting

NextCure, Inc. Presents Phase 1b Data on NC410 and Pembrolizumab Combination at ASCO 2024

New major risk - Revenue and earnings growth

NextCure, Inc., Annual General Meeting, Jun 20, 2024

NextCure, Inc. and LigaChem Biosciences, Inc. Present Preclinical Data on B7-H4 Antibody Drug Conjugate At AACR 2024

NextCure, Inc. Appoints Rakesh Dixit to Scientific Advisory Board

Recent updates

NextCure, Inc. Reports Preclinical Data for LNCB74 and Additional Clinical Biomarker Data for NC410 Combo At Society for Immunotherapy of Cancer Annual Meeting

NextCure, Inc. Presents Phase 1b Data on NC410 and Pembrolizumab Combination at ASCO 2024

New major risk - Revenue and earnings growth

NextCure, Inc., Annual General Meeting, Jun 20, 2024

NextCure, Inc. and LigaChem Biosciences, Inc. Present Preclinical Data on B7-H4 Antibody Drug Conjugate At AACR 2024

NextCure, Inc. Appoints Rakesh Dixit to Scientific Advisory Board

New major risk - Revenue and earnings growth

New major risk - Revenue and earnings growth

NextCure Presents Preclinical Data on a Novel Therapeutic Candidate Targeting VSTM-1 for the Treatment of Progressive Inflammatory Airway Disorders

Nextcure, Inc. Publishes Non-Clinical Data Demonstrating Anti-Siglec-15 Treatment Prevented Bone Loss Due to Immobilization from Acute Spinal Cord Injury

Nextcure, Inc. Provides Year-End Clinical Pipeline Updates

NextCure, Inc. Publishes Non-Clinical Data Defining the Mechanism of Action for NC525, a Novel LAIR-1 Antibody for AML

NextCure, Inc. Announces Presentation of New Preclinical Data Demonstrate Treatment with NC605

NextCure, Inc. Presents Preclinical Data on Nc181, A Novel Therapeutic Candidate Targeting Apoe4, for the Treatment of Alzheimer's Disease

NextCure, Inc. Announces Resignation of Garry A. Nicholson as from the Board of Directors

NextCure Presents Initial Data from Clinical Trial of NC762 and a Trial in Progress Poster for NC410 Combo at the 2022 Society for Immunotherapy of Cancer Annual Meeting

NextCure, Inc. Appoints Lisa M. Coussens to Scientific Advisory Board

NextCure, Inc. Announces Initiation of Phase 1b/2 Clinical Trial to Evaluate NC410 in Combination with KEYTRUDA (Pembrolizumab) in Patients with Immune Checkpoint Refractory or Naïve Solid Tumors

NextCure, Inc. Presents NC410 Data at the Extracellular Matrix Pharmacology Congress in Europe on Overcoming Clinical Limitations to Immunotherapy Through Remodeling Tumor ECM

Nextcure, Inc. Appoints Dr. Segal to Its Scientific Advisory Board

NextCure, Inc., Annual General Meeting, Jun 23, 2022

NextCure and the National Cancer Institute Announce Preclinical Data in Journal of Clinical Investigation

High number of new directors

High number of new directors

NextCure, Inc. and Collaborators Provide Data on Targets in Development at American Society of Hematology Annual Meeting

High number of new directors

Independent Director Xiaoxing Xu has left the company

NextCure, Inc.(NasdaqGS:NXTC) dropped from Russell 2500 Growth Index

Nextcure and Collaborators Publish Preclinical Data on Novel Immunomedicine Nc410

Independent Director has left the company

Full year 2020 earnings released: US$1.33 loss per share (vs US$2.15 loss in FY 2019)

Revenue misses expectations

NextCure, Inc. Announces Resignation of Briggs Morrison from the Board of Directors, Effective April 1, 2021

The Schall Law Firm Announces the Filing of A Class Action Lawsuit Against Nextcure, Inc

New 90-day high: €10.30

NextCure, Inc. Announces the Appointment of Han Myint as Chief Medical Officer

NextCure, Inc. Provides Updates on NC318 Clinical Program

New 90-day high: €10.10

Rosen Reminds Nextcure, Inc. Investors of Important November 20 Deadline in Securities Class Action

Revenue in line with expectations

Bernstein Liebhard Reminds Investors of the Deadline to File Lead Plaintiff Motion in Securities Class Action Lawsuit Against Nextcure Inc

Block & Leviton LLP Reminds Investors of Nextcure, Inc. for Violations of the Federal Securities Laws

New 90-day low: €7.25

Nextcure, Inc. Announces Resignation of Kevin N. Heller from Chief Medical Officer

Scott+Scott Attorneys At Law LLP Files Securities Class Action Against NextCure Inc

New 90-day low - €7.65

First half earnings released

NextCure, Inc.(NasdaqGS:NXTC) dropped from Russell Microcap Value Index

NextCure, Inc.(NasdaqGS:NXTC) dropped from Russell Microcap Index

NextCure, Inc.(NasdaqGS:NXTC) dropped from S&P Biotechnology Select Industry Index

Rendimenti per gli azionisti

Volatilità dei prezzi

Informazioni sull'azienda

NextCure, Inc. Riepilogo dei fondamenti

0.0x

-0.7x

Guadagni e ricavi